NCT06235697 - Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment | Biotech Hunter

Enrollment

710

Participants

Timeline

Start Date

April 25, 2024

Primary Completion Date

October 31, 2032

Study Completion Date

April 30, 2033

Conditions

Prostate Cancer

Interventions

RADIATION

Radiation

"46Gy / 23 fractions of EBRT to pelvis and prostate + LDR or HDR boost to prostate OR 25Gy / 5 fractions of EBRT to pelvis and prostate (ultrahypofractionation EBRT (SBRT)) + LDR or HDR boost to prostate.~\+ Adjuvant ADT: Unfavourable Intermediate Risk: 6 months or High / Very High Risk: 24 months"

RADIATION

Radiation SBRT only

25Gy / 5 fractions to pelvis + 40 Gy / 5 fractions to prostate (SBRT) (ultrahypofractionation EBRT (SBRT))

DRUG

ADT

Assigned at enrollment

Trial Locations (13)

23114

RECRUITING

Bon Secours Saint Francis Medical Center, Midlothian

23230

RECRUITING

Bon Secours Cancer Institute at Reynolds Crossing, Richmond

23298

RECRUITING

Virginia Commonwealth University/Massey Cancer Center, Richmond

63110

RECRUITING

Washington University School of Medicine, St Louis

63129

RECRUITING

Siteman Cancer Center-South County, St Louis

63136

RECRUITING

Siteman Cancer Center at Christian Hospital, St Louis

63141

RECRUITING

Siteman Cancer Center at West County Hospital, Creve Coeur

63376

RECRUITING

Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters

L5M 2N1

RECRUITING

Trillium Health Partners - Credit Valley Hospital, Mississauga

L1G 2B9

RECRUITING

Lakeridge Health Oshawa, Oshawa

M4N 3M5

RECRUITING

Odette Cancer Centre- Sunnybrook Health Sciences Centre, Toronto

M5G 2M9

RECRUITING

University Health Network-Princess Margaret Hospital, Toronto

H3T 1E2

RECRUITING

Jewish General Hospital, Montreal